Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease

被引:13
作者
van Trier, Tinka J. [1 ]
Snaterse, Marjolein [1 ]
Hageman, Steven H. J. [2 ]
ter Hoeve, Nienke [3 ,4 ]
Sunamura, Madoka [3 ,5 ]
Moll van Charante, Eric P. [6 ]
Galenkamp, Henrike [7 ]
Deckers, Jaap W. [8 ]
Martens, Fabrice M. A. C. [9 ]
Visseren, Frank L. J. [2 ]
Scholte Op Reimer, Wilma J. M. [1 ,10 ]
Peters, Ron J. G. [1 ]
Jorstad, Harald T. [1 ]
机构
[1] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Cardiol, Amsterdam Cardiovasc Sci, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Med Ctr Utrecht, Dept Vasc Med, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[3] Capri Cardiac Rehabil Rotterdam, Max Euwelaan 55, NL-3062 MA Rotterdam, Netherlands
[4] Erasmus MC, Dept Rehabil Med, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands
[5] St Franciscus Gasthuis, Dept Cardiol, Kleiweg 500, NL-3045 PM Rotterdam, Netherlands
[6] Amsterdam Univ Med Ctr, Dept Gen Practice, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[7] Amsterdam Univ Med Ctr, Amsterdam Publ Hlth Res Inst, Dept Publ & Occupat Hlth, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[8] Erasmus MC, Dept Cardiol, Thoraxctr, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands
[9] Deventer Hosp, Dept Cardiol, N Bolkesteinlaan 75, NL-7416 SE Deventer, Netherlands
[10] HU Univ Appl Sci Utrecht, Res Grp Chron Dis, Padualaan 99, NL-3584 CH Utrecht, Netherlands
关键词
Risk stratification; Lifetime risk; Cardiovascular risk factors; Secondary prevention; Residual risk; MYOCARDIAL-INFARCTION; WAIST CIRCUMFERENCE; EUROPEAN GUIDELINES; PREVENTION PROGRAM; CLINICAL-PRACTICE; LIFE-STYLE; CARDIOLOGY; COUNTRIES; THERAPY; SOCIETY;
D O I
10.1093/eurjpc/zwad038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Most patients with atherosclerotic cardiovascular disease remain at (very) high risk for recurrent events due to suboptimal risk factor control. Aims This study aimed to quantify the potential of maximal risk factor treatment on 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events in patients 1 year after a coronary event. Methods and results Pooled data from six studies are as follows: RESPONSE 1, RESPONSE 2, OPTICARE, EUROASPIRE IV, EUROASPIRE V, and HELIUS. Patients aged >= 45 years at >= 6 months after coronary event were included. The SMART-REACH score was used to estimate 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events with current treatment and potential risk reduction and gains in event-free years with maximal treatment (lifestyle and pharmacological). In 3230 atherosclerotic cardiovascular disease patients (24% women), at median interquartile range (IQR) 1.1 years (1.0-1.8) after index event, 10-year risk was median (IQR) 20% (15-27%) and lifetime risk 54% (47-63%). Whereas 70% used conventional medication, 82% had >= 1 drug-modifiable risk factor not on target. Furthermore, 91% had >= 1 lifestyle-related risk factor not on target. Maximizing therapy was associated with a potential reduction of median (IQR) 10-year risk to 6% (4-8%) and of lifetime risk to 20% (15-27%) and a median (IQR) gain of 7.3 (5.4-10.4) atherosclerotic cardiovascular disease event-free years. Conclusions Amongst patients with atherosclerotic cardiovascular disease, maximizing current, guideline-based preventive therapy has the potential to mitigate a large part of their risk of recurrent events and to add a clinically important number of event-free years to their lifetime. Lay Summary Patients with heart disease are at high risk of new cardiac events. This study amongst 3230 patients who had a heart attack or received a stent or bypass surgery shows missed potential for healthy life after a heart attack. The average age of study patients was 61 years, and 24% were women. At 1 year after the cardiac event, nearly one in three (30%) continued smoking, 79% were overweight, 45% reported insufficient physical activity, 40% had high blood pressure, and 65% had a too high LDL ('bad') cholesterol. We calculated that adherence to lifestyle advice and medications could on average halve the risk for another heart attack and add over 7 healthy years of life after a heart attack. This highlights the importance of healthy lifestyle and medication adherence after a heart attack. Key finding:center dot adherence to lifestyle advice and medications could add over 7 healthy years of life after a heart attack
引用
收藏
页码:601 / 610
页数:10
相关论文
共 49 条
  • [1] Development of health-related waist circumference thresholds within BMI categories
    Ardern, CI
    Janssen, I
    Ross, R
    Katzmarzyk, PT
    [J]. OBESITY RESEARCH, 2004, 12 (07): : 1094 - 1103
  • [2] Clinical Utility of Waist Circumference in Predicting All-cause Mortality in a Preventive Cardiology Clinic Population: A PreCIS Database Study
    Bajaj, Harpreet S.
    Brennan, Danielle M.
    Hoogwerf, Byron J.
    Doshi, Krupa B.
    Kashyap, Sangeeta R.
    [J]. OBESITY, 2009, 17 (08) : 1615 - 1620
  • [3] Population median imputation was noninferior to complex approaches for imputing missing values in cardiovascular prediction models in clinical practice
    Berkelmans, Gijs F. N.
    Read, Stephanie H.
    Gudbjornsdottir, Soffia
    Wild, Sarah H.
    Franzen, Stefan
    van der Graaf, Yolanda
    Eliasson, Bjorn
    Visseren, Frank L. J.
    Paynter, Nina P.
    Dorresteijn, Jannick A. N.
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2022, 145 : 70 - 80
  • [4] Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?
    Gijs F. N. Berkelmans
    Jacoba P. Greving
    Yolanda van der Graaf
    Frank L. J. Visseren
    Jannick A. N. Dorresteijn
    [J]. Diagnostic and Prognostic Research, 4 (1)
  • [5] Secondary prevention medications after coronary artery bypass grafting and long-term survival: a population-based longitudinal study from the SWEDEHEART registry
    Bjoerklund, Erik
    Nielsen, Susanne J.
    Hansson, Emma C.
    Karlsson, Martin
    Wallinder, Andreas
    Martinsson, Andreas
    Tygesen, Hans
    Romlin, Birgitta S.
    Malm, Carl Johan
    Pivodic, Aldina
    Jeppsson, Anders
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 (17) : 1653 - 1661
  • [6] Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
    Cannon, Christopher P.
    Blazing, Michael A.
    Giugliano, Robert P.
    McCagg, Amy
    White, Jennifer A.
    Theroux, Pierre
    Darius, Harald
    Lewis, Basil S.
    Ophuis, Ton Oude
    Jukema, J. Wouter
    De Ferrari, Gaetano M.
    Ruzyllo, Witold
    De Lucca, Paul
    Im, KyungAh
    Bohula, Erin A.
    Reist, Craig
    Wiviott, Stephen D.
    Tershakovec, Andrew M.
    Musliner, Thomas A.
    Braunwald, Eugene
    Califf, Robert M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (25) : 2387 - 2397
  • [7] The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
    Dhindsa, Devinder S.
    Sandesara, Pratik B.
    Shapiro, Michael D.
    Wong, Nathan D.
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2020, 7
  • [8] Dibben G, 2021, COCHRANE DB SYST REV, DOI [10.1002/14551858.CD001800.pub4, 10.1002/14651858.CD001800.pub4]
  • [9] How to translate clinical trial results into gain in healthy life expectancy for individual patients
    Dorresteijn, Jannick A. N.
    Kaasenbrood, Lotte
    Cook, Nancy R.
    van Kruijsdijk, Rob C. M.
    van der Graaf, Yolanda
    Visseren, Frank L. J.
    Ridker, Paul M.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2016, 352
  • [10] Eikelboom JW, 2018, NEW ENGL J MED, V378, P397